Citations

Clear

18 citation(s) found for "Roberts, Jason A".

Consensus Guidance for Beta‐Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiolog
Frazee, Erin N. , McCreary, Erin K. , Mangalore, Rekha Pai , Girdwood, Sonya Tang , Arriola, Rebecca, Bens, Cynthia, Bonomo, Robert A. , Edginton, Andrea N. , Hong, Lisa , Huttner, Angela , Maranchick, Nicole, Röhr, Anka C., Zuluaga, Andrés F. , Frazee, Erin N , Pai Mangalore, Rekha , Tang Girdwood, Sonya , Hong, Lisa T , Koch, Birgit C P , Maranchick, Nicole , Neely, Michael N , Peloquin, Charles A , Rao, Gauri G , Roberts, Jason A , Scheetz, Marc H , Schuetz, Audrey N , Yarnold, Paul R , Zuluaga, Andres , Rhodes, Nathaniel J , Bonomo, Robert A , McCreary, Erin K , Neely, Michael , Peloquin, Charles A. , Röhr, Anka C., Scheetz, Marc H. , Schuetz, Audrey N. , Rhodes, Nathaniel J.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | July 23, 2026 | Volume: 46 | Issue: 8 | Pages: No page available

10.1002/phar.70181 | PMID 42487243 Get It

ABSTRACT Beta‐lactam antibiotics (beta‐lactams) are first‐line treatments for most major infectious syndromes in acutely ill patients, with in vitro activity against common pathogens, demonstrated efficacy in trials, and a perceived low risk of adverse effects. The current dosing approach, informed by population‐level data, tends to be simplistically reduced to a “one size fits all” dosing method which only accounts for body weight (i.e., in pediatrics) and end organ function to estimate drug clearance (e.g., estimated glomerular filtration rate); this approach results in substantial variability in observed serum concentrations in acutely ill patients, which can compromise real‐world effectiveness and safety. Beta‐lactam dose individualization, therefore, defined as a dosing regimen for one patient informed by measured concentrations from that patient, has been recommended in international clinical guidelines. Comprehensive guidance on best practices for beta‐lactam dose individualization is lacking. To address this knowledge gap and develop guidance, a multidisciplinary panel of international experts was assembled from the disciplines of infectious diseases, critical care, pharmacometrics, and laboratory medicine, representing both adults and pediatrics. The panel systematically evaluated the literature, using the GRADE approach where feasible, to address broad thematic questions pertaining to whether beta‐lactam dose individualization should be pursued, for what indications beta‐lactam dose individualization is warranted, and the most critical considerations and best practices for implementation of beta‐lactam individualization. The resultant consensus recommendations will equip healthcare professionals caring for acutely ill patients treated with beta‐lactam therapy with the evidence and tools necessary to guide optimal use of beta‐lactam dose individualization.
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification
Lieve, Krystien V.V. , Werf, Christian van der , Kallas, Dania , Denjoy, Isabelle , Bos, J Martijn , Aiba, Takeshi , Behr, Elijah R. , Berg, Maarten P van den, Bergeman, Auke T. , Blom, Nico A. , Borggrefe, Martin , Mora, Lidia María Carrillo , Chorin, Ehud , Franciosi, Sonia , Giudicessi, John R. , Llopis, Francisco Ángel González , Heuvel, Freek van den , Ingles, Jodie , Kammeraad, Janneke A.E. , Khan, Habib R, MacIntyre, Ciorsti , Maltret, Alice , Marjamaa, Annukka, Ohno, Seiko , Peltenburg, Puck J. , Perez, Guillermo J, Roberts, Jason D, Robyns, Tomas , Noguer, Ferran Roses I., Roston, Thomas M. , Rydberg, Annika , Sacher, Frédéric , Semsarian, Christopher , Starling, Luke, Skinner, Jonathan R, Tavačová, Terézia , Tfelt‐Hansen, Jacob , Till, Janice A, Yap, Sing‐Chien , Wada, Yuko, Wangüemert, Fernando , Zorio, Esther , Ackerman, Michael J, Wilde, Arthur A, Khan, Habib , Lieve, Krystien V , van der Werf, Christian , Brugada, Ramón , Carrillo Mora, Lidia María , Chorin, Ehud , Crotti, Lia , Davis, Andrew , Drago, Fabrizio , Dusi, Veronica , Extramiana, Fabrice , Franciosi, Sonia , Giudicessi, J R , González Llopis, Francisco Ángel , Haugaa, Kristina , van den Heuvel, Freek , Horie, Minoru , Ingles, Jodie , Kammeraad, Janneke A E , Kannankeril, Prince J , Krahn, Andrew D , MacIntyre, Ciorsti , Maltret, Alice , Ohno, Seiko , Peltenburg, Puck J , Probst, Vincent , Robyns, Tomas , Rootwelt-Norberg, Christine , Roston, Thomas M , Rydberg, Annika , Sacher, Frederic , Sarquella-Brugada, Georgia , Schwartz, Peter J. , Semsarian, Christopher , Shimizu, Wataru , Sumitomo, Naokata , Tavacova, Terezia , Tfelt-Hansen, Jacob , Yap, Sing-Chien , Wangüemert, Fernando , Zorio, Esther , Leenhardt, Antoine , Sanatani, Shubhayan , Tanck, Michael , Behr, Elijah Raphael , Denjoy, Isabelle , Blom, Nico A , Kallas, Dania , Bos, J Martijn , Aiba, Takeshi , Berg, Maarten P van den, Bergeman, Auke T , Borggrefe, Martin , Khan, Habib R, Marjamaa, Annukka, Perez, Guillermo J, Roberts, Jason D, Noguer, Ferran Roses I., Starling, Luke, Skinner, Jonathan R, Till, Janice A, Wada, Yuko, Ackerman, Michael J, Leenhardt, Antoine , Wilde, Arthur A.M.

Mayo Clinic

European Heart Journal | November 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurheartj/ehaf965 | PMID 41416846 Get It

Abstract Background and Aims Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for potentially life-threatening arrhythmic events (AEs) even while treated with β-blockers. The aim was to develop a model for individualized prediction of AEs in patients with RYR2-mediated CPVT on β-blocker monotherapy. Methods The derivation and independent validation cohorts included 743 and 129 patients, respectively. AEs were defined as arrhythmic syncope, appropriate implantable cardioverter–defibrillator shock, sudden cardiac arrest (SCA), and sudden cardiac death. Near-fatal or fatal AEs (nf/fAEs) included all AEs except for arrhythmic syncope. Prediction models using Cox regression were developed and internally and externally validated. Results A total of 102 (13.7%) patients in the derivation cohort and 24 (18.6%) patients in the validation cohort experienced ≥1 AE over a median follow-up of 5.1 [interquartile range (IQR), 7.7] and 2.4 (IQR, 4.4) years, respectively. Predictors of AE were arrhythmic syncope or SCA prior to diagnosis and age at β-blocker initiation. In the derivation and validation cohorts, the optimism-corrected C-indices of the models for AE were 0.67 [95% confidence interval (CI) 0.62–0.72] and 0.59 (95% CI 0.48–0.71), respectively. For nf/fAEs, ventricular arrhythmia severity before β-blocker initiation was a fourth independent predictor, and C-indices of the models in the derivation and validation cohorts were 0.74 (95% CI 0.68–0.80) and 0.60 (95% CI 0.47–0.72), respectively. In the derivation cohort, calibration slopes were 1.00 (95% CI 0.59–1.41) for AE and 1.00 (95% CI 0.69–1.32) for nf/fAE. Conclusions These externally validated risk prediction models using clinical parameters accurately distinguished CPVT patients on β-blocker monotherapy at low and high risk for future AEs while treated with β-blockers. These models provide guidance for implementation of clinical management therapies to prevent AEs in patients with CPVT.
A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome
Ni, Mingke , Saenen, Johan , Hoeksema, Wiert F. , Antiperovitch, Pavel , Arnaud, Marine , Tian, Shanshan, Sun, Bo , Estillore, John Paul , Wang, Ruiwu , Khan, Habib , Roston, Thomas M. , Mazzanti, Andrea , Giudicessi, John, Siontis, Konstantinos C. , Alak, Aiman, Acosta, J. Gabriel , Menon, Syamkumar M. Divakara, Tan, Nigel S. , Vivekanantham, Hari , Pandya, Tanvi, Cunningham, Jennifer , Gula, Lorne J. , Wong, Jorge , Amit, Guy , Scheinman, Melvin M. , Ackerman, Michael J. , Priori, Silvia G. , Sacher, Frédéric , Nof, Eyal , Glikson, Michael , Wilde, Arthur A.M. , Jensen, Henrik Kjærulf , Chen, S.R. Wayne , Roberts, Jason D. , Jensen, Henrik Kjærulf , Mazzanti, Andrea , Priori, Silvia , Dadon, Ziv , Ormerod, Julian O.M. , Tadros, Rafik , Christiansen, Morten Krogh , Steinberg, Christian , Giudicessi, John R. , Werf, Christian van der , Nazer, Babak , Krahn, Andrew D. , Gollob, Michael H. , Healey, Jeff S. , Glikson, Michael , Watkins, Hugh , Postema, Pieter G. , Belhassen, Bernard

Mayo Clinic

JAMA | June 20, 2024 | Volume: 332 | Issue: 3 | Pages: 204

10.1001/jama.2024.8599 | PMID 38900490 Get It

Importance Sudden death and cardiac arrest frequently occur without explanation, even after a thorough clinical evaluation. Calcium release deficiency syndrome (CRDS), a life-threatening genetic arrhythmia syndrome, is undetectable with standard testing and leads to unexplained cardiac arrest. Objective To explore the cardiac repolarization response on an electrocardiogram after brief tachycardia and a pause as a clinical diagnostic test for CRDS. Design, Setting, and Participants An international, multicenter, case-control study including individual cases of CRDS, 3 patient control groups (individuals with suspected supraventricular tachycardia; survivors of unexplained cardiac arrest [UCA]; and individuals with genotype-positive catecholaminergic polymorphic ventricular tachycardia [CPVT]), and genetic mouse models (CRDS, wild type, and CPVT were used to define the cellular mechanism) conducted at 10 centers in 7 countries. Patient tracings were recorded between June 2005 and December 2023, and the analyses were performed from April 2023 to December 2023. Intervention Brief tachycardia and a subsequent pause (either spontaneous or mediated through cardiac pacing). Main Outcomes and Measures Change in QT interval and change in T-wave amplitude (defined as the difference between their absolute values on the postpause sinus beat and the last beat prior to tachycardia). Results Among 10 case patients with CRDS, 45 control patients with suspected supraventricular tachycardia, 10 control patients who experienced UCA, and 3 control patients with genotype-positive CPVT, the median change in T-wave amplitude on the postpause sinus beat (after brief ventricular tachycardia at ≥150 beats/min) was higher in patients with CRDS ( P < .001). The smallest change in T-wave amplitude was 0.250 mV for a CRDS case patient compared with the largest change in T-wave amplitude of 0.160 mV for a control patient, indicating 100% discrimination. Although the median change in QT interval was longer in CRDS cases ( P = .002), an overlap between the cases and controls was present. The genetic mouse models recapitulated the findings observed in humans and suggested the repolarization response was secondary to a pathologically large systolic release of calcium from the sarcoplasmic reticulum. Conclusions and Relevance There is a unique repolarization response on an electrocardiogram after provocation with brief tachycardia and a subsequent pause in CRDS cases and mouse models, which is absent from the controls. If these findings are confirmed in larger studies, this easy to perform maneuver may serve as an effective clinical diagnostic test for CRDS and become an important part of the evaluation of cardiac arrest.
Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe
Carrick, Richard , Marco, Corrado De , Gasperetti, Alessio , Bosman, Laurens P. , Trancuccio, Alessandro , Mazzanti, Andrea , Murray, Brittney , Pendleton, Catherine, Tichnell, Crystal , Tandri, Harikrishna , Zeppenfeld, Katja , Wilde, Arthur A.M. , Davies, Brianna , Seifer, Colette , Roberts, Jason D. , MacIntyre, Ciorsti, Alqarawi, Wael , Cutler, Michael J. , Targetti, Mattia , Calò, Leonardo , Vitali, Francesco , Compagnucci, Paolo , Cappelletto, Chiara, Duru, Fırat , Jensen, Henrik Kjærulf , Svensson, Anneli , Dahlberg, Pia , Hasselberg, Nina E. , Marco, Andrea Di , Jordà, Paloma , Weidmann, Zoraida Moreno , Borowiec, Karolina , Delinière, Antoine , Tintelen, J. Peter van , Olivotto, Iacopo , Saguner, Ardan M. , Cox, Moniek G.P.J. , Merlo, Marco , Riele, Anneline S.J.M. te , Wu, Kathérine C. , Calkins, Hugh , James, Cynthia A. , Cadrin‐Tourigny, Julia , Carrick, Richard T , De Marco, Corrado , Gourraud, Jean-Baptiste , Trancuccio, Alessandro , Mazzanti, Andrea , Murray, Brittney , Zeppenfeld, Katja , Davies, Brianna , Alqarawi, Wael , Bertini, Matteo , Compagnucci, Paolo , Cappelletto, Chiara , Stolfo, Davide , Duru, Firat , Di Marco, Andrea , Arbelo, Elena , Delinière, Antoine , Saguner, Ardan M , Merlo, Marco , Krahn, Andrew D , Te Riele, Anneline S J M , Calkins, Hugh , James, Cynthia A , Cadrin-Tourigny, Julia , van Tintelen, J Peter , Olivotto, Iacopo , Jensen, Henrik Kjærulf , Gourraud, Jean‐Baptiste , Healey, Jeff S. , Tadros, Rafik , Casella, Michela , Russo, Antonio Dello , Luca, Antonio De , Arbelo, Elena , Biernacka, Elżbieta Katarzyna , Platonov, Pyotr G. , Haugaa, Kristina H. , Tondo, Claudio , Krahn, Andrew D.

Mayo Clinic

European Heart Journal | January 10, 2024 | Volume: 45 | Issue: 7 | Pages: 538-548

10.1093/eurheartj/ehad799 | PMID 38195003 Get It

Abstract Background and Aims Implantable cardioverter-defibrillators (ICDs) are critical for preventing sudden cardiac death (SCD) in arrhythmogenic right ventricular cardiomyopathy (ARVC). This study aims to identify cross-continental differences in utilization of primary prevention ICDs and survival free from sustained ventricular arrhythmia (VA) in ARVC. Methods This was a retrospective analysis of ARVC patients without prior VA enrolled in clinical registries from 11 countries throughout Europe and North America. Patients were classified according to whether they received treatment in North America or Europe and were further stratified by baseline predicted VA risk into low- (<10%/5 years), intermediate- (10%–25%/5 years), and high-risk (>25%/5 years) groups. Differences in ICD implantation and survival free from sustained VA events (including appropriate ICD therapy) were assessed. Results One thousand ninety-eight patients were followed for a median of 5.1 years; 554 (50.5%) received a primary prevention ICD, and 286 (26.0%) experienced a first VA event. After adjusting for baseline risk factors, North Americans were more than three times as likely to receive ICDs {hazard ratio (HR) 3.1 [95% confidence interval (CI) 2.5, 3.8]} but had only mildly increased risk for incident sustained VA [HR 1.4 (95% CI 1.1, 1.8)]. North Americans without ICDs were at higher risk for incident sustained VA [HR 2.1 (95% CI 1.3, 3.4)] than Europeans. Conclusions North American ARVC patients were substantially more likely than Europeans to receive primary prevention ICDs across all arrhythmic risk strata. A lower rate of ICD implantation in Europe was not associated with a higher rate of VA events in those without ICDs.
Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Bergeman, Auke T. , Lieve, Krystien V.V. , Kallas, Dania , Bos, J. Martijn , Noguer, Ferran Rosés i, Denjoy, Isabelle , Zorio, Esther , Kammeraad, Janneke A.E. , Peltenburg, Puck J. , Tobert, Katie, Aiba, Takeshi , Batra, Anjan S. , Borggrefe, Martin , Cox, Moniek G.P.J. , Dhillon, Santokh , Etheridge, Susan P. , Fischbach, Peter , Franciosi, Sonia , Horie, Minoru , Johnsrude, Christopher L. , Kane, Austin, Krause, Ulrich , Kwok, Sit‐Yee , Ohno, Seiko , Roberts, Jason D. , Robyns, Tomas , Sacher, Frédéric , Semsarian, Christopher , Swan, Heikki, Tavačová, Terézia , Tisma‐Dupanovic, Svjetlana , Tfelt‐Hansen, Jacob , Yap, Sing‐Chien , Till, Janice, Sanatani, Shubhayan , Ackerman, Michael J. , Wilde, Arthur A.M. , Rosés‐Noguer, Ferran , Atallah, Joseph , Drago, Fabrizio , Brugada, Ramón , Borggrefe, Martin , Clur, Sally-Ann B , Cox, Moniek G P J , Davis, Andrew , Dhillon, Santokh , Etheridge, Susan P , Haugaa, Kristina , Horie, Minoru , Johnsrude, Christopher , Krause, Ulrich , LaPage, Martin J , Ohno, Seiko , Probst, Vincent , Roberts, Jason D , Robyns, Tomas , Sacher, Frederic , Semsarian, Christopher , Skinner, Jonathan R , Tavacova, Terezia , Tisma-Dupanovic, Svjetlana , Tfelt-Hansen, Jacob , Yap, Sing-Chien , Kannankeril, Prince J , Leenhardt, Antoine , Sanatani, Shubhayan , Ackerman, Michael J , Wilde, Arthur A M , van der Werf, Christian , Bos, Johan M , Zorio, Esther , Denjoy, Isabelle , Rosés-Noguer, Ferran , Kammeraad, Janneke A E , Lieve, Krystien V , Peltenburg, Puck J , Aiba, Takeshi , Atallah, Joseph , Clur, Sally‐Ann B. , Davis, Andrew M. , Haugaa, Kristina H. , Skinner, Jonathan R. , Kannankeril, Prince J. , Leenhardt, Antoine , Tanck, Michael , Werf, Christian van der , Bergeman, Auke T

Mayo Clinic

Circulation | October 27, 2023 | Volume: 148 | Issue: 25 | Pages: 2029-2037

10.1161/circulationaha.123.064786 | PMID 37886885 Get It

BACKGROUND: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia. METHODS: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy. The study period was defined as the period in which background therapy (ie, beta-blocker type [beta1-selective or nonselective]), left cardiac sympathetic denervation, and implantable cardioverter defibrillator treatment status, remained unchanged within individual patients and was divided into pre-flecainide and on-flecainide periods. The primary end point was AEs, defined as sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter defibrillator shock, and arrhythmic syncope. The association of flecainide with AE rates was assessed using a generalized linear mixed model assuming negative binomial distribution and random effects for patients. RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14–29]; median flecainide dose, 2.2 mg/kg per day [interquartile range, 1.7–3.1]) were included. At baseline, all patients used a beta-blocker, 70 (28%) had an implantable cardioverter defibrillator, and 21 (9%) had a left cardiac sympathetic denervation. During a median pre-flecainide follow-up of 2.1 years (interquartile range, 0.4–7.2), 41 patients (17%) experienced 58 AEs (annual event rate, 5.6%). During a median on-flecainide follow-up of 2.9 years (interquartile range, 1.0–6.0), 23 patients (9%) experienced 38 AEs (annual event rate, 4.0%). There were significantly fewer AEs after initiation of flecainide (incidence rate ratio, 0.55 [95% CI, 0.38–0.83]; P =0.007). Among patients who were symptomatic before diagnosis or during the pre-flecainide period (n=167), flecainide was associated with significantly fewer AEs (incidence rate ratio, 0.49 [95% CI, 0.31–0.77]; P =0.002). Among patients with ≥1 AE on beta-blocker therapy (n=41), adding flecainide was also associated with significantly fewer AEs (incidence rate ratio, 0.25 [95% CI, 0.14–0.45]; P <0.001). CONCLUSIONS: For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.
Why is the Implementation of Beta-Lactam Therapeutic Drug Monitoring for the Critically Ill Falling Short? A Multicenter Mixed-Methods Study
Frazee, Erin N. , Chitre, Pooja N., Shepel, Kathryn, Aziz, Mohd. Hafiz Abdul, Ausman, Sara , Moreland-Head, Lindsay N, Jannetto, Paul J. , Mara, Kristin C. , Boehmer, Kasey R. , Shepel, Kathryn K, Ausman, Sara E., Mara, Kristin C , Chitre, Pooja , Pine, Kathleen H. , Rule, Andrew D. , Al‐Shaer, Mohammad H. , Abdul-Aziz, Mohd Hafiz , Roberts, Jason A , Scheetz, Marc H. , Ausman, Sara E , Rivera, Christina G.

Mayo Clinic

Therapeutic Drug Monitoring | April 20, 2023 | Volume: 45 | Issue: 4 | Pages: 508-518

10.1097/ftd.0000000000001059 | PMID 37076424 Get It

Background: Beta-lactam therapeutic drug monitoring (BL TDM; drug level testing) can facilitate improved outcomes in critically ill patients. However, only 10%–20% of hospitals have implemented BL TDM. This study aimed to characterize provider perceptions and key considerations for successfully implementing BL TDM. Methods: This was a sequential mixed-methods study from 2020 to 2021 of diverse stakeholders at 3 academic medical centers with varying degrees of BL TDM implementation (not implemented, partially implemented, and fully implemented). Stakeholders were surveyed, and a proportion of participants completed semistructured interviews. Themes were identified, and findings were contextualized with implementation science frameworks. Results: Most of the 138 survey respondents perceived that BL TDM was relevant to their practice and improved medication effectiveness and safety. Integrated with interview data from 30 individuals, 2 implementation themes were identified: individual internalization and organizational features. Individuals needed to internalize, make sense of, and agree to BL TDM implementation, which was positively influenced by repeated exposure to evidence and expertise. The process of internalization appeared more complex with BL TDM than with other antibiotics (ie, vancomycin). Organizational considerations relevant to BL TDM implementation (eg, infrastructure, personnel) were similar to those identified in other TDM settings. Conclusions: Broad enthusiasm for BL TDM among participants was found. Prior literature suggested that assay availability was the primary barrier to implementation; however, the data revealed many more individual and organizational attributes, which impacted the BL TDM implementation. Internalization should particularly be focused on to improve the adoption of this evidence-based practice.
743. Implementation of Beta-Lactam Therapeutic Drug Monitoring Programs in the Critically Ill: A Multicenter Mixed-Methods Study
Ausman, Sara , Boehmer, Kasey R. , Chitre, Pooja N., Saleh, Omar Abu , Abdul-Aziz, Hafiz, Jannetto, Paul J. , Moreland-Head, Lindsay , Shepel, Kathryn, Frazee, Erin N. , Ausman, Sara E , Chitre, Pooja , Pine, Kathleen H. , Al‐Shaer, Mohammad H. , Gajic, Ognjen , Mara, Kristin C. , Rivera, Christina G. , Roberts, Jason A , Rule, Andrew D. , Scheetz, Marc H.

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.034 Get It

Abstract Background Beta-lactam therapeutic drug monitoring (BL TDM; drug level testing) can facilitate improved outcomes in critically ill patients. Yet less than 20% of hospitals have implemented BL TDM. The purpose of this study was to characterize provider perceptions and key considerations for successful implementation of BL TDM. Methods This was a sequential mixed methods study from 2020 to 2021 of stakeholders at three academic medical centers with varying degrees of BL TDM implementation - Mayo Clinic (BL TDM not implemented), University of Florida Health Shands (partially implemented), and Royal Brisbane and Women’s Hospital (fully implemented). Stakeholders completed a survey to characterize their knowledge, perceptions, and experience with BL TDM. A diverse group of 30 respondents were then purposively sampled for semi-structured interviews. Results from the two strands were integrated, themes were identified, and findings were situated within implementation science frameworks. Results Among the 138 survey respondents (22% response rate), the majority were physicians (38%) and pharmacists (33%). 71% practiced in critical care and 21% in infectious diseases. The majority of respondents felt BL TDM was relevant to their practice and improved medication effectiveness and safety (Figure 1). Two implementation themes were identified: individual internalization and organizational features. Individuals needed to internalize, make sense of, and agree to BL TDM implementation which was positively influenced by repeated exposure to evidence and expertise. The process of internalization seemed more complex with BL TDM than with other antibiotics (i.e., vancomycin). Organizational considerations relevant to BL TDM implementation included adequate physical and informational infrastructure, access to trained personnel, supportive governance/leadership, and robust process and workflow development. Conclusion We found broad enthusiasm about the relevance and potential benefits of BL TDM among stakeholders. Prior literature suggested the primary barrier to implementation was assay availability, but we identified many more individual and organizational attributes which impacted the scale and spread of BL TDM. Disclosures Sara Ausman, PharmD, Gilead: Honoraria Christina G. Rivera, PharmD, Gilead: Grant/Research Support|Gilead: Honoraria|Insmed: Honoraria Jason Roberts, BPharm(Hons), PhD, FSHP, FISAC, British Society of Chemotherapy: Grant/Research Support|Cipla: Honoraria|Gilead: Advisor/Consultant|MSD: Advisor/Consultant|MSD: Honoraria|Pfizer: Board Member|Pfizer: Honoraria|Qpex: Grant/Research Support|Sandoz: Board Member|Summit: Advisor/Consultant|Wolters Kluwer: Advisor/Consultant Marc H. Scheetz, PharmD, MSc, Abbvie: Advisor/Consultant|Allecra: Grant/Research Support|Merck: Advisor/Consultant|Nevakar: Advisor/Consultant|Nevakar: Grant/Research Support|Premier Healthcare Solutions: Honoraria|Spero: Advisor/Consultant|SuperTrans Medical: Advisor/Consultant|SuperTrans Medical: Grant/Research Support|Takeda: Advisor/Consultant|Third Pole Therapeutics: Advisor/Consultant.
A lipoglycopeptide antibiotic for Gram-positive biofilm-related infections
Blaskovich, Mark A. T. , Hansford, Karl A. , Butler, Mark S. , Ramu, Soumya , Kavanagh, Angela M. , Prasetyoputri, Anggia , Pitt, Miranda E. , Huang, Johnny X. , Lindahl, Fredrik, Ziora, Zyta M. , Bradford, Tanya A. , Muldoon, Craig, Premraj, Rajaratnam , Pelingon, Ruby , Edwards, David J. , Amado, Maite , Woischnig, Anne-Kathrin , Breidenstein, Elena B. M. , Stincone, Anna, Karau, Melissa J. , Greenwood‐Quaintance, Kerryl E. , Wootton, Mandy , James, Meagan L. , Hutton, M. , Mahdi, Layla K. , Trott, Darren J. , Wu, Xiaoqian, Niles, Samantha , Lewis, Kim , Yim, Juwon , Rice, Seth, Rybak, Michael J. , Ishmael, Chad R. , Hori, Kellyn R. , Francis, Kevin P. , Jarrad, Angie M , Prasetyoputri, Anggia , Pitt, Miranda E , Huang, Johnny X , Ziora, Zyta M , Bradford, Tanya , Rajaratnam, Premraj , Pelingon, Ruby , Zhang, Bing , Elliott, Alysha G , Zuegg, Johannes , Coin, Lachlan , Khanna, Nina , Stincone, Anna , Mason, Clive , Cho, Hye-Kyung , Karau, Melissa , Greenwood-Quaintance, Kerryl , Patel, Robin , Wootton, Mandy , James, Meagan L , Hutton, Melanie L , Lyras, Dena , Ogunniyi, Abiodun D , Mahdi, Layla K , Niles, Samantha , Lewis, Kim , Smith, Jordan R , Barber, Katie E , Rybak, Michael J , Ishmael, Chad R , Hori, Kellyn R , Bernthal, Nicholas M , Francis, Kevin P , Paterson, David L. , Cooper, Matthew A , Blaskovich, Mark A T , Edwards, David J., Khan, Nawaz, Patel, Robin , Roberts, Jason A

Mayo Clinic

Science Translational Medicine | September 14, 2022 | Volume: 14 | Issue: 662 | Pages: No page available

10.1126/scitranslmed.abj2381 | PMID 36103517 Get It

Drug-resistant Gram-positive bacterial infections are still a substantial burden on the public health system, with two bacteria ( Staphylococcus aureus and Streptococcus pneumoniae ) accounting for over 1.5 million drug-resistant infections in the United States alone in 2017. In 2019, 250,000 deaths were attributed to these pathogens globally. We have developed a preclinical glycopeptide antibiotic, MCC5145, that has excellent potency (MIC 90 ≤ 0.06 μg/ml) against hundreds of isolates of methicillin-resistant S. aureus (MRSA) and other Gram-positive bacteria, with a greater than 1000-fold margin over mammalian cell cytotoxicity values. The antibiotic has therapeutic in vivo efficacy when dosed subcutaneously in multiple murine models of established bacterial infections, including thigh infection with MRSA and blood septicemia with S. pneumoniae , as well as when dosed orally in an antibiotic-induced Clostridioides difficile infection model. MCC5145 exhibited reduced nephrotoxicity at microbiologically active doses in mice compared to vancomycin. MCC5145 also showed improved activity against biofilms compared to vancomycin, both in vitro and in vivo, and a low propensity to select for drug resistance. Characterization of drug action using a transposon library bioinformatic platform showed a mechanistic distinction from other glycopeptide antibiotics.
An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia
Peltenburg, Puck J. , Kallas, Dania , Bos, J. Martijn , Lieve, Krystien V.V. , Franciosi, Sonia , Roston, Thomas M. , Denjoy, Isabelle , Sorensen, Katrina B. , Ohno, Seiko , Rosés‐Noguer, Ferran , Aiba, Takeshi , Maltret, Alice , Atallah, Joseph , Giudicessi, John R. , Tanck, Michael W.T. , Kato, Koichi , Barc, Julien , Borggrefe, Martin, Behr, Elijah R. , Tfelt‐Hansen, Jacob , Zorio, Esther , Swan, Heikki, Kammeraad, Janneke A.E. , Sacher, Frédéric , Roberts, Jason D. , Berg, Maarten P. van den , Robyns, Tomas , Tavačová, Terézia , Semsarian, Christopher , Till, Jan , Horie, Minoru , Ackerman, Michael J. , Sanatani, Shubhayan , Wilde, Arthur A.M. , Bos, Johan M , LaPage, Martin J , Atallah, Joseph , Giudicessi, J R , Clur, Sally-Ann B , Tanck, Michael , Extramiana, Fabrice , Kato, Koichi , Barc, Julien , Behr, Elijah Raphael , Tfelt-Hansen, Jacob , Zorio, Esther , Krahn, Andrew D , Davis, Andrew , Sacher, Frederic , Schwartz, Peter J. , Roberts, Jason D , Skinner, Jonathan R , van den Berg, Maarten P , Kannankeril, Prince J , Drago, Fabrizio , Robyns, Tomas , Haugaa, Kristina , Tavacova, Terezia , Semsarian, Christopher , Probst, Vincent , Brugada, Ramón , Shimizu, Wataru , Horie, Minoru , Leenhardt, Antoine , Ackerman, Michael J , Sanatani, Shubhayan , Wilde, Arthur A M , Denjoy, Isabelle , Rosés-Noguer, Ferran , Lieve, Krystien V , Peltenburg, Puck J , Ohno, Seiko , Aiba, Takeshi , Clur, Sally‐Ann B. , Blom, Nico A. , Sarquella-Brugada, Georgia , Krahn, Andrew D. , Davis, Andrew M. , Skinner, Jonathan R. , Kannankeril, Prince J. , Haugaa, Kristina H. , Leenhardt, Antoine , Werf, Christian van der

Mayo Clinic

Circulation | December 7, 2021 | Volume: 145 | Issue: 5 | Pages: 333-344

10.1161/circulationaha.121.056018 | PMID 34874747 Get It

Background: Symptomatic children with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for recurrent arrhythmic events. β-Blockers decrease this risk, but studies comparing individual β-blockers in sizeable cohorts are lacking. We aimed to assess the association between risk for arrhythmic events and type of β-blocker in a large cohort of symptomatic children with CPVT. Methods: From 2 international registries of patients with CPVT, RYR2 variant–carrying symptomatic children (defined as syncope or sudden cardiac arrest before β-blocker initiation and age at start of β-blocker therapy <18 years), treated with a β-blocker were included. Cox regression analyses with time-dependent covariates for β-blockers and potential confounders were used to assess the hazard ratio (HR). The primary outcome was the first occurrence of sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter-defibrillator shock, or syncope. The secondary outcome was the first occurrence of any of the primary outcomes except syncope. Results: We included 329 patients (median age at diagnosis, 12 [interquartile range, 7–15] years, 35% females). Ninety-nine (30.1%) patients experienced the primary outcome and 74 (22.5%) experienced the secondary outcome during a median follow-up of 6.7 (interquartile range, 2.8–12.5) years. Two-hundred sixteen patients (66.0%) used a nonselective β-blocker (predominantly nadolol [n=140] or propranolol [n=70]) and 111 (33.7%) used a β1-selective β-blocker (predominantly atenolol [n=51], metoprolol [n=33], or bisoprolol [n=19]) as initial β-blocker. Baseline characteristics did not differ. The HRs for both the primary and secondary outcomes were higher for β1-selective compared with nonselective β-blockers (HR, 2.04 [95% CI, 1.31–3.17]; and HR, 1.99 [95% CI, 1.20–3.30], respectively). When assessed separately, the HR for the primary outcome was higher for atenolol (HR, 2.68 [95% CI, 1.44–4.99]), bisoprolol (HR, 3.24 [95% CI, 1.47–7.18]), and metoprolol (HR, 2.18 [95% CI, 1.08–4.40]) compared with nadolol, but did not differ from propranolol. The HR of the secondary outcome was only higher in atenolol compared with nadolol (HR, 2.68 [95% CI, 1.30–5.55]). Conclusions: β1-selective β-blockers were associated with a significantly higher risk for arrhythmic events in symptomatic children with CPVT compared with nonselective β-blockers, specifically nadolol. Nadolol, or propranolol if nadolol is unavailable, should be the preferred β-blocker for treating symptomatic children with CPVT.